Bivirkninger rapporteret hos mindst 5% af patienterne i nogle af behandlingsgrupperne - studie 11213 for nyrecellecancer (se studie 1 under pkt.
Adverse reactions reported in at least 5% of patients in any treatment group – study 11213 in renal cell carcinoma (see study 1 in section 5.1).